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Metalloproteases play a fundamental role in snake venom envenomation inducing hemorrhagic, ﬁbrige-
n(ogen)olytic and myotoxic effects in their victims. Several snake venoms, such as those from the Bothrops
genus, present important local effects which are not efﬁciently neutralized by conventional serum therapy.
Consequently, these accidents may result in permanent sequelae and disability, creating economic and
social problems, especially in developing countries, leading the attention of the World Health Organization
that considered ophidic envenomations a neglected tropical disease. Aiming to produce an efﬁcient in-
hibitor against bothropic venoms, we synthesized different molecules classiﬁed as quinolinones e a group
of low-toxic chemical compounds widely used as antibacterial and antimycobacterial drugs e and tested
their inhibitory properties against hemorrhage caused by bothropic venoms. The results from this initial
screening indicated the molecule 2-hydroxymethyl-6-methoxy-1,4-dihydro-4-quinolinone (Q8) was the
most effective antihemorrhagic compound among all of the assayed synthetic quinolinones. Other in vitro
and in vivo experiments showed this novel compound was able to inhibit signiﬁcantly the hemorrhagic
and/or proteolytic activities of bothropic crude venoms and isolated snake venom metalloproteases
(SVMPs) even at lower concentrations. Docking and molecular dynamic simulations were also performed to
get insights into the structural basis of Q8 inhibitory mechanism against proteolytic and hemorrhagic
SVMPs. These structural studies demonstrated that Q8 may form a stable complex with SVMPs, impairing
the access of substrates to the active sites of these toxins. Therefore, both experimental and structural data
indicate that Q8 compound is an interesting candidate for antiophidic therapy, particularly for the treat-
ment of the hemorrhagic and necrotic effects induced by bothropic venoms.
© 2015 Elsevier B.V. and Societe Française de Biochimie et Biologie Moleculaire (SFBBM). All rights
reserved.e Biofísica, Instituto de Bio-
istrito de Rubi~ao Júnior, S/N,
essos e Biotecnologia, Facul-
mpus de Botucatu, Fazenda
80, CEP:18.610-307, Botucatu,
agro), fontes@ibb.unesp.br
de Biochimie et Biologie Molecul1. Introduction
Snake venoms are complex mixtures of several proteins
including phospholipases A2, phospholipases A2-like, metal-
loproteases, serineproteases, L-amino oxidases, disintegrins, C- type
lectins and others. Their combination are able to unleash a complex
series of events responsible for the pathophysiology of snake en-
venomation and the consequent emergence of deleteriousaire (SFBBM). All rights reserved.
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edema-inducing activity, hemorrhage, coagulation and several
other properties [15].
Recent proteomic analyses indicated that snake venom metal-
loproteases (SVMPs), which are composed by a group of zinc-
dependent enzymes, are the most representative toxins present
in viperid species [1e9] and also are found in Colubridae [10e12];
Elapidae [13e16] and Atractaspididae [17] families. According to
the revised classiﬁcation of SVMPs by Fox and Serrano [18,19], these
molecules are distributed in three different classes, depending on
their molecular weight and domain structure. i) small SVMPs
(20e30 kDa) with only a single catalytic domain in the P-I class; ii)
medium SVMPs (30e60 kDa) composed by catalytic and
disintegrin-like domains in the P-II class; and iii) large SVMPs
(60e100 kDa) with catalytic, disintegrin-like and cysteine-rich
domains in the P-III class (the large SVMPs with an extra lectin-
like domain are also included in the P-III class).
Initially, the main role attributed to SVMPs was related to the
remarkable hemorrhagic activity presented by many of these
molecules (particularly the large SVMPs). This biological property is
clearly linked to their ability to interact with speciﬁc receptors on
endothelial cells [20,21] and ﬁbroblasts [22] and is also involved in
the degradation of extracellular matrix components [23]. However,
a wide spectrum of other SVMP functions have been described in
the last years, comprising very distinct capabilities as ﬁbrin(ogen)
olytic activity, inactivation of blood serine proteinase inhibitors,
prothrombin and blood coagulation factor X activation, platelet
aggregation inhibition, apoptosis induction, and pro-inﬂammatory
action [24]. All of these activities presented by SVMPs contribute to
the systemic actions observed after envenomation, but the inﬂu-
ence of these toxins on the local effects is especially critical, since
they contribute strongly to severe tissue necrosis resulting from
their hemorrhagic and proteolytic activities [25]. Hence, as serum
therapy is not effective enough to avoid the occurrence of local
effects caused by viperid venoms, it is quite interesting to search for
new molecules which could be also used in anti-snake venom
treatments.
In many countries, including Brazil, plant extracts are tradi-
tionally used for the treatment of snakebite envenomations,
although there is scientiﬁc validation only in a few cases [26e30].
On the other hand, several isolated plant alkaloids have been
described as in vitro and in vivo anti-snake venom inhibitors
[30e35]. Thus, we synthesized different quinolinone molecules e
low-toxic chemical compounds [36] which are already widely used
as antibacterial and antimycobacterial drugs [37,38] e and tested
their inhibitory properties against hemorrhage caused by Bothrops
jararacussu, Bothrops moojeni and Bothrops alternatus venoms and
the isolated P-III class SVMP BjussuMP-I from B. jararacussu. The
results obtained from this initial screening pointed out the most
effective antihemorrhagic molecule was the compound 2-
hydroxymethyl-6-methoxy-1,4-dihydro-4-quinolinone (identiﬁed
herein as Q8). Subsequently, other in vitro and in vivo experiments
showed the novel Q8 compound was able to signiﬁcantly inhibit,
even at lower concentrations, the hemorrhagic and/or proteolytic
activities of four bothropic crude venoms (B. jararacussu, Bothrops
neuwiedi, B. moojeni and B. alternatus) and two isolated SVMPs (P-III
class BjussuMP-I from B. jararacussu and P-I class neuwiedase from
B. neuwiedi).
Additionally, docking and molecular dynamics simulations
involving BjussuMP-II, a P-I SVMP from B. jararacussu venom [39]
with a very well characterized proteolytic activity, and Q8 com-
pound were performed to get some insights into the inhibitory
activity of this novel 4-quinolinone molecule against the action of
SVMPs. These theoretical studies are justiﬁed since proteolysis is a
common feature of SVMPs related to local tissue damage andhemorrhage. Therefore, the structural basis related to the harmful
activities of the SVMP catalytic domains is a important topic for the
identiﬁcation of potential compounds for snake envenomation
treatment.
2. Materials and methods
2.1. Materials and chemicals
All commercially available reagents were purchased from
Aldrich Chemical Co. Reagents® and solvents were puriﬁed when
necessary according to the usual procedures described in the
literature. B. jararacussu, B. neuwiedi, B. moojeni and B. alternatus
venoms were purchased from Bioagents Serpentarium Ltda.
(Batatais, S~ao Paulo State, Brazil). The SVMPs (P-III class BjussuMP-I,
P-I class BjussuMP-II and P-I class neuwiedase) were isolated and
biochemically characterized as previously described [39e41]. The
licenses for scientiﬁc purposes are from Instituto Brasileiro do Meio
Ambiente e dos Recursos Naturais Renovaveis e IBAMA and Instituto
Chico Mendes de Conservaç~ao da Biodiversidade e ICMBio. Numbers:
11094-2, 11094-1, 10394-1 and 15484-1.
The infrared spectra were measured on a Bomem M102® spec-
trometer (4000 - 400 cm1). NMR data assignment was based on
1H and 13C and the spectra were recorded on a Bruker DRX-200®
and ARX-400®. Mass spectral analyses were carried out with a
Shimadzu GCMS-QP5000® spectrophotometer. Analytical thin-
layer chromatography was performed on a 0.25 mm ﬁlm of silica
gel containing a ﬂuorescent indicator UV254 supported on
aluminum sheet (SigmaeAldrich®). Flash column chromatography
was executed using a silica gel (Kieselgel 60, 230e400 mesh, E.
Merck®). Gas chromatography was performed in a Shimadzu GC-
17A® chromatograph equipped with a DB-5 column, employing H2
as a carrier. Elemental analyses and the melting points were per-
formed, respectively, with Fisons EA1108 CHNS-O® analyzer and
FISATOM 430® equipment. Melting points were determined using a
Microquimica MQAPF-301® device.
2.2. Compounds and procedures employed for 2-hydroxymethyl-6-
methoxy-1,4-dihydro-4-quinolinone (Q8) synthesis
2.2.1. General procedure for the synthesis of enamines
In a ﬂask under N2 at 55 C containing aniline (5.0 g, 0.054 mol)
or p-anisidine (5.0 g, 0.041 mol) in dry methanol (1 mL/mmol an-
iline), DMAD (1 eq.) was added and the mixture was stirred over-
night. Then methanol was removed under reduced pressure, and
CH2Cl2 (30 mL) was added followed by a saturated solution of
NH4Cl (3  5 mL). The organic layer was dried over anhydrous
MgSO4, and evaporated to dryness under reduced pressure. The
residue was puriﬁed on a silica gel column, using hexane:ethyl
acetate 9.5:0.5 as eluent to afford desired enamine compounds 3 or
4 in 50% yield.
2.2.1.1. 2-Phenylamino-2-enediocic acid dimethyl ester (compound
3). 6.3 g. IR (nmax, ﬁlm, cm1): 3457; 3380; 2953; 1739; 1668; 1282;
1031. 1H NMR (200 MHz, CDCl3): d 9.67 (sl, 1H); 7.32e7.25 (m, 2H);
7.13e7.05 (m,1H); 6.9 (m, 2H); 5.39 (s,1H); 3.74 (s; 3H); 3.70 (s, 3H).
13C NMR (50MHz, CDCl3) d: 169.8; 164.7; 147.9; 140.2; 129.0; 124.1;
120.6; 116.6; 93.5; 52.6; 51.1. MS (% rel. intensity) m/z: 235.25
(6.9%); 144.15 (93.3%); 77.10 (100%).
2.2.1.2. 2-(4-Methoxy-phenylamino)-2-enediocic acid dimethyl ester
(compound 4). 5.5 g. IR (nmax, ﬁlm, cm1): 3284; 3210; 2952; 2836;
1742; 1637; 1033. 1H NMR (200 MHz, CDCl3): d. 9.57 (sl, 1H);
6.91e679 (m, 4H); 5.30 (s, 1H); 3.78 (s, 3H); 3.73 (s, 3H); 3.67 (s,
3H). 13C NMR (50 MHz, CDCl3) d: 182.4; 170.0; 164.8; 156.9; 149.0;
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265.50 (12.6%); 146.15 (74.6%); 77.15 (96.5%).
2.2.2. General procedure for the synthesis of 4-quinolinone
compounds 5 and 6
A ﬂask adapted with a condenser containing diphenyl ether
(8 mL) was heated in a sand bath up to the reﬂux temperature and
then enamine compounds 3 or 4 (1.0 g) were added. The mixture
was stirred for 10 min and transferred to an ice bath. The residue
was puriﬁed by dry ﬂash chromatography using a hexane e
methylene chloride e MeOH gradient to afford the desired 4-
quinolinone compounds 5 or 6 in 70% yield.
2.2.2.1. Methyl-4-oxo-1,4-dihydroquinolinone 2-carboxylate (com-
pound 5). 0.6 g mp: 215e217 C. IR (nmax, ﬁlm, cm1): 3436; 2925;
2886; 1733; 1639; 1538; 1033. 1H NMR (200 MHz, CDCl3): 12.03 (s,
1H); 8.13 (d, J ¼ 8.0 Hz, 1H); 7.95 (d, J ¼ 10 Hz, 1H); 7.66e7.63 (m,
1H); 7.35e7.32 (m,1H); 6.73 (s; 1H); 3.99 (s; 3H). 13C NMR (50MHz,
CDCl3) d: 176.4; 161.1; 138.4; 135.8; 130.6; 124.4; 123.0; 122.1;
117.9; 108.8; 51.5. MS (% rel. intensity)m/z: 203 (30.1%); 143 (100%);
115.15 (72.9%); 89.15 (66.2%).
2.2.2.2. Methyl-6-methoxy-4-oxo-1,4-dihydro-quinolinone carbox-
ylate (compound 6). 0.53 g mp: 250e253 C. IR (nmax, ﬁlm, cm1):
3440; 2935; 2865; 1729; 1639; 1552; 1024. 1H NMR (200 MHz,
CDCl3): d 12.14 (s, 1H); 7.92 (d, J ¼ 9.1 Hz, 1H); 77.46 (d, J ¼ 2.8 Hz,
1H); 7.37 (dd, J ¼ 9.0, 2.8 Hz, 1H); 6.67 (s; 1H); 3.96 (s; 3H); 3.85 (s;
3H). 13C NMR (50 MHz, CDCl3) d: 176.3; 162.3; 155.8; 136.2; 134.2;
126.7; 122.8; 120.9; 108.3; 103.2; 54.9; 52.9. MS (% rel. intensity)m/
z: 207.50 (54.5%); 173.2 (91%); 73.2 (100%).
2.2.3. General procedure for the synthesis of 4-quinolinone
compounds 7 and 8
In a ﬂask containing 4-quinolinone compounds 5 or 6 (0.50 g) in
dry THF (10 mL) under N2 at 0 C, BH3.SMe2 (1 eq) was added drop
wise. The mixture was allowed to warm to room temperature
overnight. Then dry methanol (3  10 mL) was added, the solvent
was evaporated under atmospheric pressure and the crude product
was recrystallized to furnish 4-quinolinone compounds 7 or 8 in
70% yield.
2.2.3.1. 2-Hydroxymethyl-1,4-dihydro-4-quinolinone (compound 7).
0.3 g mp: 230e232 C. IR (nmax, ﬁlm, cm1): 3384; 2946; 2917;
1619; 1359; 1083. 1H NMR (200MHz, CDCl3): d. 8.04 (dd, J¼ 8, 1 Hz,
1H); 7.69e7.56 (m, 2H); 7.31e7.23 (m, 1H); 6.02 (s, 1H); 4.48 (s,
2H).13C NMR (50 MHz, CDCl3) d: 153.5; 140.4; 131.6; 125.3; 125.0;
122.9; 118.6; 105.6; 60.5. Anal. Calcd for C10H9NO2:C, 68.56%; H,
5.18%; N, 8.0%. Found: C, 68.60%; H, 5.18%; N, 7.90%.
2.2.3.2. 2-Hydroxymethyl-6-methoxy-1,4-dihydro-4-quinolinone
(compound 8 or Q8). 0.3 g mp: 250e252 C. IR (nmax, ﬁlm, cm1):
3448; 2921; 2852; 1637; 1504; 1035. 1H NMR (200 MHz, CDCl3):
d 7.94 (dd, J ¼ 8.4.1 Hz, 1H); 7.52e7.41 (m, 2H); 6.63 (s, 1H); 4.72 (s,
2H); 3.89 (s, 3H).13C NMR (50 MHz, CDCl3) d: 171.5; 156.8; 155.5;
134.5; 124.2; 123.2; 121.0; 103.1; 102.7; 60.0; 55.6. Anal. Calcd. for
C11H11NO3: C, 64.38%; H, 5.4%; N, 6.83%. Found: C, 64.41%; H, 5.55%;
N, 6.81%.
2.2.4. General procedure for the synthesis of quinolines 9, 10 and 11
To a ﬂask containing compound 6 or 8 (0.1 mmol) and K2CO3
(20.7 mg, 0.15 mmol) it was added anhydrous DMF (50 mL) and
ethyl bromide (9.5 mL, 0.15 mmol). The ﬂask was stirred for 12 h at
room temperature. The solution was ﬁltered in silica to remove the
precipitate and the solvent was evaporated, then the resulting
material was puriﬁed by column chromatography in silica gel usinga gradient of n-hexane emethanol as eluent furnishing products 9
and 10 in 80% yield.
2.2.4.1. 4-ethoxy-6-methoxy-2-quinoline methyl carboxylate (com-
pound 9). 17 mg mp: 105e107

C. IR (nmax, KBr) cm1: 2933; 2856;
1730; 1639; 1483; 1236; 1024. 1H NMR (400 MHz, CDCl3) d: 8.11 (d,
J ¼ 9.2 Hz, 1H); 7.55 (s, 1H); 7.46 (d, J ¼ 2.8 Hz, 1H); 7.48 (dd, J ¼ 9.2,
2.8 Hz, 2H); 4.36 (q, J ¼ 7 Hz, 2H); 4.06 (s, 3H); 3.96 (s, 3H); 1.60 (t,
J ¼ 7 Hz, 3H). 13C NMR (100 MHz, CDCl3) d: 166.46; 161.29; 158.91;
146.60; 144.42; 131.82; 123.42; 123.02; 101.01; 99.61; 64.53; 55.64;
53.08; 14.48.
2.2.4.2. 4-ethoxy-6-methoxy-2-quinolilmethanol (compound 10).
mp: 120e123 C. IR (nmax, KBr) cm1: 2947; 2866; 1643; 1592;
1382; 1031; 825. 1H NMR (400 MHz, CDCl3) d: 7.77 (d, J ¼ 9.14 Hz,
1H); 7.42 (d, J ¼ 2.7 Hz, 1H); 7.32 (dd, J ¼ 9.2, 2.9 Hz, 1H); 7.55 (s,
1H); 4.75 (s, 2H); 4.31 (q, J ¼ 7.0 Hz, 2H); 3.88 (s, 3H); 1.55 (t,
J ¼ 7 Hz, 3H). 13C NMR (100 MHz, CDCl3) d: 162.11; 161.19; 157.41;
144.63; 130.72; 122.52; 121.52; 100.73; 99.72; 65.86; 64.91; 56.35;
15.33.
2.2.4.3. 4-ethoxy-2-ethoxymethyl-6-methoxyquinoline (compound
11). In a suspension of NaH 60% (3 mg, 0.077 mmol) in dry DMF
(100 mL) and DME (500 mL) was added a solution of compound 8
(15 mg, 0.064 mmol) in DME (100 mL) at 0 C. After 10 min the
mixture was treated with LiBr (12 mg, 0.128 mmol) and stirred by
15 min. Then ethyl bromide was added (8.3 mg, 0.077 mmol)
dropwise. The mixture was stirred at room temperature by 3 h;
after ice addition, it was extracted with ethyl acetate (3  10 mL)
and the combined organic phases where washed with brine
(3  5 mL). The resulting solution was dried with anhydrous so-
dium sulfate and the solvent was evaporated. The crude material
was puriﬁed using column chromatography in silica gel with hex-
ane:ethyl acetate 6:4 as eluent. Compound 11 was obtained in 80%
yield (13.3 mg). mp: 69e72 C. IR (nmax, KBr) cm1: 2975; 2931;
2886; 1704; 1596; 1224; 1093; 831. 1H NMR (400 MHz, CDCl3) d:
7.88 (d, J ¼ 9.1 Hz, 1H); 7.44 (d, J ¼ 2.8 Hz, 1H); 7.32 (dd, J ¼ 9.1,
2.8 Hz,1H); 6.94 (s, 1H); 4.71 (s, 2H); 4.30 (q, J¼ 7.0 Hz, 2H); 3.93 (s,
3H); 3.64 (q, J¼ 7 Hz, 2H), 1.57 (t, J¼ 7 Hz, 3H), 1.29 (t, J¼ 7 Hz, 3H).
13C NMR (100MHz, CDCl3) d: 161.27; 158.11; 157.12; 144.39; 129.92;
121.97; 99.98; 98.82; 74.39; 66.35; 64.09; 55.56; 15.28; 14.55.
2.3. Biological assays
Animal procedures were in accordance with the guidelines for
animal care prepared by the Committee on Care and Use of Labo-
ratory Animal Resources, National Research Council, USA. Animal
care was in accordance with the guidelines of the Brazilian College
for Animal Experimentation (COBEA) and was approved by Com-
mittee for Ethics in Animals Utilization of USP/Campus Ribeir~ao
Preto-SP (Process n 07.1.517.53.6).
2.3.1. Hemorrhagic activity
50 mg of desiccated crude venoms (B. jararacussu, B. moojeni and
B. alternatus) and freeze-dried SVMP BjussuMP-I from B. jararacussu
were weighed and dissolved in phosphate-buffered saline (PBS, pH
7.2), while the synthetic compounds, named 5 through 11 were
dissolved in DMSO, including the compound of interest, Q8. For the
initial screening, Swiss male mice (18e22 g, n ¼ 6) were injected
intradermically (50 mL) in the back region with different pre-
incubated (30 min; 37 C) doses containing different crude
venoms/SVMPs:5 through 11 compounds at a 1:10 proportion (w/
w). Control mice received PBS or DMSO. Three hours after injection,
the mice were sacriﬁced and the diameter of the hemorrhagic spot
on the back skin was measured [39,40].
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bition test was performed, (i) one with pre-incubation (30 min;
37 C) of the venoms/metalloproteases with different doses of the
compound Q8 (1:5, 1:10, 1:15 and 1:30, w/w); and (ii) a post-
envenoming test, where ﬁrst the mice only received intradermal
injections containing BjussuMP-I (50 mg/50 mL), and after 15 min,
the same animals were inoculated by the same route with the
compound Q8 in the proportions 1:30 and 1:100 (SVMP: Q8, w/w).
The assessment of the hemorrhagic activity was conducted in the
same manner and three hours after injection, mice were killed and
the diameter of the hemorrhage zone in the skin was measured.
2.3.2. Proteolytic activity on casein
40 mg of crude snake venoms (B. jararacussu and B. neuwiedi) or
SVMPs BjussuMP-I from B. jararacussu and neuwiedase from
B. neuwiedi previously incubated with Q8 at different w/w ratios
(1:5, 1:10, 1:15 and 1:30), were incubated with 1.0 mL of 1% (w/v)
casein in 0.1 M TriseHCl buffer (pH 8.0) for 30 min at 37 C. The
reaction was blocked by the addition of 1.0 mL of 5% (v/v) tri-
chloroacetic acid solution and the mixture remained at room
temperature for 30 min before centrifugation (2000  g) for
5 min at 25 C. Proteolytic activity was estimated bymonitoring the
absorbance of the clear supernatant at 280 nm [39,40].
2.3.3. Statistical analysis
Results are presented as the mean value ± SD obtained with the
indicated number of tested animals. The statistical signiﬁcance of
differences between groups was evaluated using Student's un-
paired t-test. A P value < 0.05 was considered to indicate
signiﬁcance.
2.4. Computational procedures
2.4.1. BjussuMP-II modeling
According to the alignment data from the based-threading
method program HHpred [42], available at the Max-Planck Insti-
tute for Developmental Biology server (http://toolkit.tuebingen.
mpg.de/hhpred), a 1.05 Å resolution crystallographic model of the
zinc metalloproteinase BaP1 from Bothrops asper snake venom
complexed to a peptidomimetic inhibitor [43] (PDB code 2w15)
was selected as a template for the construction of the native P-I
class BjussuMP-II structural model. This template, selected in the
Protein Data Base (PDB) using the algorithm BlastP (default pa-
rameters), was chosen based on the alignment score (337.81) and
its identity (81%) to the BaP1 sequence. The programModeller 9v10
[44] was then used to generate ten structural models based on the
selected template, keeping the original position of the cofactor
Zn2þ. Additionally, the 1.93 Å resolution crystallographic model of
the native zinc metalloproteinase BaP1 [45] from Bothrops asper
(PDB code 1nd1) was also added to the Modeller 9v10 alignment
input to deﬁne the position of the Glu42/Zn2þ-coordinated catalytic
water molecule in the generated models. Variable target function
method (VTFM) with conjugate gradients (CG) [44] and molecular
dynamics (MD) [44] with simulated annealing (SA) [44] were used
in order to reﬁne the models. The Zn2þ cofactor of each model was
added based on the coordinates of this ion in the BaP1/peptido-
mimetic inhibitor crystallographic model. The best BjussuMP-II
model was selected according to the stereochemical and energy
parameters determined respectively by the programs RAMPAGE
[46] and ProSA-web [47].
2.4.2. Q8 in silico design and docking simulations
The program Avogadro v.0.9.4 [48] was used to design Q8 and
improve its overall structure by an energy minimization process
based on the MMF94 force ﬁeld and in a steepest-descentalgorithm. All docking simulations between the native BjussuMP-II
model and the ligand were executed by the program Gold v.5.0.1
(CCDC Software Limited, Cambridge, U.K.) [49]. The docking site
was deﬁned within a 20 Å radius around the cofactor Zn2þ localized
at the protein active site. The docking simulations were performed
with the options on/ﬁx, on/spin, toggle/ﬁx and toggle/spin to
evaluate the inﬂuence of the Glu142/Zn2þ-coordinated catalytic
watermolecule on the docking solutions. Aminimum of ten rounds
were executed for each simulation, with the generation of twenty
docking solutions per round; the other docking parameters were
deﬁned according to the GOLD v.5.0.1 default settings. The docking
solutions between Q8 and the native BjussuMP-II model were
scored using the GoldScore ﬁtness functions [49].
2.4.3. Molecular dynamics simulations
The BjussuMP-II/Q8 docking solutions which presented the
highest GoldScore values were submitted to molecular dynamics
(MD) simulations using the program GROMACS (Groningen Ma-
chine for Chemical Simulation) v.4.5.4 [50,51]. The GROMOS 96
53a6 force ﬁeld [52] was chosen to perform the MD simulations
and the protonation states of the charged groups were set to pH 7.0.
All the MD simulations were executed in the presence of explicit
water molecules [53] and the minimum allowed distance between
any atom of the models and the box wall was set to 1.0 nm. An
energy minimization (EM) using a steepest descent algorithm was
performed to generate the starting conﬁguration of the systems.
After this step, 200 ps of MD simulation with position restraints
applied to the protein (PRMD) was executed in order to relax the
systems gently. Then, 15 ns of unrestrained MD simulation were
calculated to evaluate the stability of the structures. All MD simu-
lations were carried out in a periodic truncated cubic box under
constant temperature (298 K) and pressure (1.0 bar), which were
held by coupling to an isotropic pressure and external heat bath
[54]. The distances between the catalytic histidines and the Zn2þ
ion of the native BjussuMP-II model and the BjussuMP-II/Q8 com-
plexes were kept according to Andreini et al. [55]. Q8 topology and
coordinates ﬁles used for molecular dynamics (MD) simulations
were generated by the Dundee PRODRG2 Server (http://davapc1.
bioch.dundee.ac.uk/prodrg/).
2.4.4. Evaluation of the theoretical structural models
Overall stereochemical and energy quality of the native
BjussuMP-II model and the BjussuMP-II/Q8 complex after their
respective MD simulations were checked with the programs
RAMPAGE [46] and ProSA-web [47]. Additionally, in order to assess
the quality of the native BjussuMP-II model and BjussuMP-II/Q8
complex after their respective MD simulations, the average rmsd
(root mean square deviation)/time graph of the protein backbone
atoms were analyzed in terms of the difference between the total
averages of two equal sets of points (the transient part of the MD
simulations was not considered).
3. Results and discussion
3.1. Synthesis of 2-hydroxymethyl-6-methoxy-1,4-dihydro-4-
quinolinone (Q8)
The synthetic route to obtain 2-hydroxymethyl-6-methoxy-1,4-
dihydro-4-quinolinone (Q8) from a commercially available anisi-
line in three steps is shown in Fig. 1. The ﬁrst step involves an
enamine bond formation, which was achieved in 80% yield through
condensation of dimethyl acetylenodicarboxylate (DMAD) with the
anisiline compound 2, as described by Edmont [56]. Intramolecular
cyclization to obtain the compound 4 was performed under reﬂux
in different conditions and the best results were obtained with 70%
Fig. 1. Synthetic route to obtain 2-Hydroxymethyl-6-methoxy-1,4-dihydro-4-quinolinone (Q8) (1).
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and afterwards enamine compound 3 was added and reﬂuxed
during 10 min. In order to completely stop the reaction and
avoiding decomposition of the desired product, the ﬂask was
immediately transferred to an ice bath. The puriﬁcation of quino-
linone compound 4 was achieved using dry ﬂash with a hexane/
methylene chloride/methanol solvent gradient. The chemo-
selective reduction of quinolinone compound 4 was carried out
with BH3.SMe2, furnishing compound 8 or Q8 in good yield (~70%).
Infrared and NMR data assays were used to conﬁrm the identity of
the Q8 compound (section 2.2.3).Fig. 2. Screening all quinolinones versus crude venoms or BjussuMP-I. Effect quino-
linones (compounds 5e11) on the hemorrhage induced by Bothrops snake venoms
(B. moojeni, B. jararacussu and B. alternatus) and BjussuMP-I, a SVMP from B. jararacussu
venom.3.2. Biochemical/pharmacological trials with Q8 demonstrated its
high inhibitory efﬁcacy against crude snake venoms and SVMPs
Fig. 2 shows the initial screening of quinolinones (compounds
Q5eQ13) against crude bothropic venoms and BjussuMP-I at 1:10
w/w proportions (crude bothropic venoms/BjussuMP-
I:quinolinone). These assays showed clearly that the molecule Q8
is the most effective hemorrhagic inhibitor compared to the other
quinolinones. Taking into account the remarkable inhibitory ac-
tivity of the Q8 molecule, a further in vivo hemorrhagic experiment
was performed using pre-incubated mixtures containing different
crude bothropic venoms/BjussuMP-I:Q8 w/w proportions (Fig. 3A).
In this experiment, the crude snake venoms and BjussuMP-I which
were not pre-incubated with Q8 induced hemorrhagic spots vary-
ing from 8 to 13 mm of diameter in the back skin of the mice. In
contrast, after pre-incubation with the quinolinone compound, the
hemorrhagic spot in the back skin of the mice was clearly reduced
even considering the 1:5 w/w proportion (crude venom/BjussuMP-
I:Q8). At the minimum inhibitor proportion (1:5 w/w), the hem-
orrhagic spot diameter was, on average, around 6 mm (25%
reduction), 7 mm (42% reduction), 10 mm (23% reduction) and
5 mm (45% reduction) respectively for B. jararacussu, B. moojeni,
B. alternatus crude venoms and BjussuMP-I from B. jararacussu. The
increase in the amount of Q8 in relation to crude venoms or
BjussuMP-I showed a progressive inhibition potency, culminating
in a reduction of approximately 81.25% (~1 mm diameter), 87.5%
(~1 mm diameter), 76.9% (~3 mm diameter) and 77.8% (~2 mm
diameter) in the diameter of induced hemorrhagic spots, respec-
tively, by B. jararacussu, B. moojeni and B. alternatus crude venoms
and BjussuMP-I after pre-incubation with the maximum Q8 pro-
portion (1:30 w/w). Additionally, a post-envenoming experiment
conﬁrmed the compound Q8 was also able to inhibit the formation
Fig. 3. (A) Effect of 2-Hydroxymethyl-6-methoxy-1,4-dihydro-4-quinolinone (Q8) on the hemorrhage induced by Bothrops snake venoms (B. moojeni, B. jararacussu and
B. alternatus) and BjussuMP-I, a SVMP from B. jararacussu venom. The hemorrhagic spots on the back skin of mice were measured 3 h after intrademic injection of the crude venoms
or SVMP pre-incubated with the Q8 (30 min, 37 C) at different crude venom/BjussuMP-I:Q8 w/w ratios (1:5, 1:10, 1:15 and 1:30). In the control experiments (shown at left of the
graph), mice received PBS or DMSO. Results are expressed as mean ± S.D. (n ¼ 6). (B) Effect of Q8 on the proteolytic activity on casein induced by Bothrops snake venoms
(B. jararacussu and B. neuwiedi) and isolated SVMPs BjussuMP-I and neuwiedase from B. jararacussu and B. neuwiedi venoms, respectively. Different crude venom/SVMP: Q8 w/w
ratios (1:5, 1:10, 1:15 and 1:30) were tested to assay the Q8 inhibitory activity using a 1.0 mL 1% (w/v) casein solution. The measurements were performed after incubation (30 min,
37 C) and the proteolytic activity was estimated monitoring the absorbance of the supernatant at 280 nm at different. The control experiments are shown at left of the graph.
Results are expressed as mean ± S.D. (n ¼ 6).
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assay indicated a signiﬁcant reduction of the hemorrhagic activity
when Q8 was administered at 1:30 and 1:100 w/w (toxin/Q8)
proportions after 15 min of the BjussuMP-I injection (47% and 66%,
respectively).
Proteolytic activity of B. jararacussu and B. neuwiedi crude
venoms and the SVMPs BjussuMP-I and neuwiedase on casein was
also inhibited signiﬁcantly by Q8. In Fig. 3B, it is possible to observe
that the proteolytic activity of the control experiments (performed
without pre-incubation with Q8) presented an efﬁciency superior
to 60% for all tested crude venoms or SVMPs. In contrast, after pre-
incubation with the inhibitor, the efﬁciency of the proteolytic ac-
tivity dropped to values near 20% and 10%, respectively, for crude
venoms and SVMPs.
Therefore, the data above show that Q8 can inhibit efﬁciently
the hemorrhagic activity of some crude snake venoms and isolated
the SVMP BjussuMP-I from B. jararacussu in mice. Additionally, the
same conclusion can be drawn from experiments involving pro-
teolytic activity on casein of tested crude venoms and SVMPs. These
ﬁndings indicate the potential of Q8 as an anti-snake venom drug,
particularly for the treatment of the hemorrhagic and necrotic ef-
fects induced by the action of snake venoms and SVMPs found in
these complex biological mixtures.3.3. Structural insights into BjussuMP-II inhibition by Q8
3.3.1. BjussuMP-II structural model
According to the biochemical trials, Q8 was particularly efﬁcient
in the inhibition of hemorrhagic and proteolytic activities induced
by some crude snake venoms and snake venom metalloproteases
(SVMPs). These results suggest that the toxin and Q8 interactions
could be circumscribed to the active site and/or surroundings of
SVMPs, since the catalytic domains of these toxins are related to
these harmful pharmacological and biological properties. Hence,
docking and molecular dynamics simulations involving atheoretical model of a P-I class SVMP, which is constituted by a
single catalytic domain (present and conserved in all SVMPs), and
Q8 were performed in order to provide noteworthy insights into
the structural features of this and other similar complexes.
Initial theoretical model of the native BjussuMP-II SVMP was
built [42,44] using two crystallographic models as templates: a zinc
metalloproteinase BaP1 from B. asper snake venom complexed to a
peptidomimetic inhibitor [43] and a native metalloprotease BaP1
from B. asper [45]. This protein presents an identity degree of 81% in
relation to BjussuMP-II and the score of the alignment between
these two sequences was 417.0 [42]. The initial theoretical model of
the native BjussuMP-II was then improved through a 20 ns-MD
simulation [50,51] and it presented, after 5000 ps, a maximum
rmsd backbone atom amplitude of approximately 1.0 Å and a rmsd
backbone atom average difference around 0.1 Å between 5001-
12500 ps and 12501e20000 ps (the ﬁrst transient 5000 ps was not
considered). After the MD simulation, the ﬁnal model of the native
BjussuMP-II showed a good stereochemical quality: 96.1% of its
residues were in the core and additionally allowed regions of the
Ramachandran plot [46] and the potential energy of the entire
structure presented a negative balance (Z-score ¼ - 6.52) [47].
Based on the data showed above, it is possible to suppose that
the theoretical native BjussuMP-II model obtained after the 20 ns-
MD simulation is feasible, not showing an apparent structural
instability. The model obtained at the end of the 20 ns-MD simu-
lation also kept the structural similarity in relation to other
experimentally-determined SVMP catalytic domains [57e64], pre-
senting three disulﬁde bridges (Cys116-Cys196, Cys156-Cys180,
and Cys158-Cys163) and two ellipsoidal subdomains: the major
one containing the ﬁrst 152 residues (four a-helicese A, B, C, and D,
and six stranded b-sheets e sI, sII, sIII, sIV, sV, and sVI) and the
minor one enclosing the remaining 98 residues (one a-helix and
several loops). Additionally, the imidazole rings from catalytic
histidines presented a favorable position to coordinate the catalytic
zinc after the 20 ns-MD simulation, reinforcing the probable
Fig. 4. BjussuMP-II/Q8 interactions. An average distance of 1.9 Å was kept between the
oxygen atom from Q8 carbonyl group and the cofactor Zn2þ during the 50 ns-MD
simulation. The distances (Å) from the catalytic histidines (His144, His148, and His154)
and Glu142/Zn2þ-coordinated catalytic water molecule (HOH) to the cofactor Zn2þ are
also shown to attest the appropriate conformation of the active site after the 50 ns-MD
simulation. This illustration was generated with program PyMOL v.1.3.
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model. Likewise, the side chain of the residue Glu142, which is
also essential for the nucleophilic attack on the scissile peptide
bond of metalloproteinase substrates [57], also remained in the
vicinity of the catalytic histidines.
3.3.2. BjussuMP-II/Q8 complex model and its comparison with
other complexed-SVMP structures
Following the 20 ns-MD simulation, a molecular docking
simulation was carried out with the ﬁnal native BjussuMP-II model
and Q8. For this purpose, the docking site of the ligand was deﬁned
as a sphere of approximately 4000 Å3 around the BjussuMP-II
catalytic ion Zn2þ. The deﬁnition of the active site and its sur-
roundings as the docking site was based on several crystallographic
experiments which indicate that these protein spots are effectively
the regions of interaction between different SVMPs and speciﬁc
inhibitors or ligands. In 1994, Zhang et al. [59], solved crystallo-
graphic complexes between atrolysin C (form d), a SVMP from
Crotalus atrox venom, and the natural PyroGlu-Asn-Trp tripeptide
and synthetic SCH47890 ligands, demonstrating that these mole-
cules bind to the atrolysin C active site region. Similarly, Cirilli et al.
[65], solved the adamalysin II from Crotalus adamanteus crystallo-
graphic structure bound to an analogue of POL647, a synthetic tri-
peptide derivative from the natural reprolysin inhibitors found in
crotalid and viperid snake venoms, and showed that the ligand
interacts with catalytic site residues and the cofactor Zn2þ in an
asymmetric bidentate, partly ﬁlling the primary speciﬁcity subsite
S1'. Furthermore, the presence of the inhibitor in this complex
displaces the catalytically essential water molecule, which is co-
ordinated by the cofactor Zn2þ and a glutamate residue in the
native protein. The non-covalent interaction of other peptidomi-
metic inhibitors (POL647 and POL656) with residues of the ada-
malysin II active site regionwas also described by Gomis-Rüth et al.
[58]. Analyzing the potential contributions of the adamalysin II/
POL647 and adamalysin II/POL656 complexes for drug design of
TACE (TNFa-converting enzymes) inhibitors, the authors indicated
that the insertion of these inhibitors in the adamalysin II active site
provoked a slight opening of the substrate-binding cleft, as also
described by Zhang et al. [61] in the complex tripeptide KNL/SVMP
F-II from Agkistrodon acutus.
Our molecular docking results showed that the best protein/
ligand solutions (GoldScore Fitness y 55) present similar orienta-
tions of Q8, which are deeply inserted into the S1'-pocket of the
native BjussuMP-II model, occupying a region nearby the helix D, b-
strand sIV, and bulged segment (a region anterior to the b-strand
sIV edge which protrudes into the active site cleft) (for a complete
description of the SVMP structural elements see the review pre-
pared by St€ocker et al. [66]). Interestingly, the analysis of these
molecular docking solutions seem to indicate that the ﬁtting of the
inhibitor does not necessarily implicate in a displacement of the
Glu142/Zn2þ-coordinated catalytic water molecule, thus indicating
that the inhibitory activity of Q8 is probably not linked to the
impairment of the dyad Glu142/reactive solvent molecule. There-
fore, according to the molecular docking simulation, the ligand
could just impair the correct contact between the components of
the catalytic site and substrate molecules, not allowing the occur-
rence of any hydrolytic reaction due to a considerable steric
hindrance.
In order to verify the feasibility of these results, the BjussuMP-II/
Q8 molecular docking solution with the highest score (GoldScore
Fitness y 55.12) was submitted to an extended MD simulation
(50 ns) to assess the stability of this complex and identify the
prevalence of possible protein/inhibitor interactions. The analysis
of the BjussuMP-II/Q8 structure after the 50 ns-MD simulation
showed a maximum rmsd backbone atom amplitude ofapproximately 0.8 Å and a rmsd backbone atom average difference
around 0.1 Å between 2001e24000 ps and 24001e50000 ps (the
ﬁrst transient 2000 ps was not considered). Consequently, as in the
ﬁrst 20 ns-MD simulation, it is possible to assume that the model of
the protein/inhibitor complex does not present an instability ten-
dency during the 50 ns-MD simulation. In addition, after this 50 ns-
MD simulation, the general stereochemistry quality (97.1% of the
residues were in the core and additionally allowed regions of the
Ramachandran plot) (46) and potential energy (47) (Z-score ¼ -
6.27) were essentially kept in comparison to the initial model ob-
tained after the 20 ns-MD simulation.
Indeed, the data from the latter MD simulation revealed more
interesting features which could shed some light on the structural
basis related to the SVMP inhibitory activity of Q8. An analysis of
the interactions between ligand and protein during the 50 ns-MD
simulation indicated that the formation of hydrogen bonds seems
not to play an essential role for the stabilization of the BjussuMP-II/
Q8 complex. The most prevalent hydrogen bond (formed between
the Q8 hydroxymethyl group and the Gln108 Nε2 atom) occurred
during only approximately 5.5% of the MD simulation (~2.75 ns),
whereas none of the remaining exceeded 1.5% (~0.75 ns). On the
other hand, an important interaction involving the oxygen atom
from the Q8 carbonyl group and the cofactor Zn2þ is observed in the
BjussuMP-II/Q8 complex, since an average distance of 1.9 Å was
kept between these atoms during all the 50 ns-MD simulation
(Fig. 4).
In fact, according to the program FindGeo [67], Q8 takes part in a
regular square pyramidal coordination of the cofactor Zn2þ, which
is completed by the Nε2 atoms from active site histidines and the
Glu142/Zn2þ-coordinated catalytic water molecule and presents a
rmsd value of only 0.312 Å in relation to the ideal geometry of this
type of coordination. Interestingly, the Zn2þ regular square coor-
dination found in the BjussuMP-II/Q8 complex is unique in com-
parison to the total of 27 native or ligand-complexed SVMP crystal
structures currently available in PDB (Protein Data Bank). This
ﬁnding, associated with the fact that this ligand apparently binds to
BjussuMP-II without displacing the Glu142/Zn2þ-coordinated
Fig. 5. Fit of Q8 (depicted in sticks) into the active site cavity of BjussuMP-II (depicted
in a surface representation). The low molecular weight and shape of the synthetic
molecule seem to be appropriate to provide an optimum access to the catalytic site,
allowing the impairing of the SVMP activity possibly by a steric hindrance mechanism.
This illustration was generated with program PyMOL v.1.3.
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crystal structure molecules, highlights the potential singular Q8
characteristics in relation to other SVMP inhibitors. A possible
explanation for these features could be the low molecular weight
(173 Da) of Q8 in comparison to other SVMP inhibitors. This
compact shape of this synthetic quinolinone probably provides
better access and an appropriate ﬁt into the BjussuMP-II active site
(Fig. 5), thus favoring the interaction between the carbonyl group
from the inhibitor and the protein cofactor Zn2þ. Therefore, it is
very plausible that Q8 is able to impair the SVMP activity by a steric
hindrance mechanism related to its remarkable compact di-
mensions. Also, this low molecular weight probably is particularly
useful for its application against local effects caused by ophidic
venoms since it allows a rapid tissue diffusion. Indeed, our in vivo
experiments support this last supposition given that the addition of
Q8 helped to reduce signiﬁcantly the myotoxic effect caused by
B. jararacussu PLA2s in mice.
Thereby, the structural analysis of the BjussuMP-II/Q8 model
underscored the potential use of this synthetic quinolinone as an
adjuvant in snakebite serum therapy, mainly in order to relieve the
hemorrhagic and proteolytic actions of the Bothrops metal-
loproteases, as previously attested by the biological and functional
assays. Moreover, future pharmacological and structural studies
involving Q8 could also reveal more important clues for the
development of structure-based drugs against defective homo-
logue proteases involved in haemostatic system diseases which
affect humans and other mammals.4. Conclusions
The experimental results indicate that Q8 is able to inhibit
signiﬁcantly hemorrhagic and/or proteolytic activities presented by
crude snake venoms from B. jararacussu, B. moojeni and B. alternatus
and the isolated metalloproteases BjussuMP-I from B. jararacussu
and neuwiedase from B. neuwiedi in mice. According to structural
studies involving docking and molecular dynamics simulations, a
possible explanation for the inhibitory properties of this quinoli-
none molecule could be its low molecular weight structure, which
allows an appropriate ﬁt into the BjussuMP-II active site. The for-
mation of a stable complex between Q8 and BjussuMP-II or other
SVMPs may, consequently, impair the access of substrates to the
active site of these toxins, explaining thus the hemorrhagic and
proteolytic inhibition veriﬁed in the experimental trials. Indeed, a
detailed analysis of the contacts formed during the MD simulation
between the residues from the BjussuMP-II active site and Q8
shows the carbonyl group from the inhibitor and the proteincofactor Zn2þ hold the main interaction responsible for the stabi-
lization of the complex BjussuMP-II/Q8. Additionally, the low mo-
lecular weight of this quinolinone probably is potentially useful for
application against local effects caused by ophidic venoms since
this characteristic could permit rapid tissue diffusion of the inhib-
itor. Therefore, the experimental and theoretical data indicate that
Q8 is an interesting drug-candidate compound for antiophidic
therapy, particularly for the treatment of hemorrhagic and necrotic
effects induced by the action of bothropic and other viperid snake
venoms.
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